TX-POWER-COSTS-INC
17.3.2021 11:02:10 CET | Business Wire | Press release
Brookfield Renewable Ireland Limited (“BRIL” or “Brookfield Renewable”) has gone live with PCI’s Enterprise Platform to manage its customer billing requirements in the Irish energy market.
As part of its partnership with Brookfield Renewable, PCI deployed its specifically tailored, cloud-based, integrated platform to replace the Irish business’ legacy system and several in-house applications. The new Customer Billing Solution implemented by PCI enables Brookfield Renewable to:
- Manage complex bilateral contracts, including power purchase agreements (PPAs)
- Leverage PCI’s settlements calculation business rules engine to perform billing allocation
- Perform counterparty checkouts and meter data management (MDM)
- Interface with upstream and downstream (physical, telemetered, and accounting) systems
- Maintain comprehensive auditability with all data versions
- Automate invoice creation and management workflows
- Drill-down and quickly extract data to perform reporting
BRIL Chief Commercial Officer Ciaran O'Brien noted, “We are excited at the launch of our new cloud-based customer billing system which will be transformational for our renewable energy business, bringing increased flexibility and supporting further growth with a scalable, best-in-class solution.” Adding, “We are proud to partner with PCI on this project and appreciate the professional collaboration with our team for an on-time and on-budget delivery.”
“We have found a great partner in Brookfield Renewable, one that has a matching ethos and customer-centric mindset. The successful go-live represents a major milestone for PCI’s global, remote software deployments that feature 24x7 operations,” said PCI Vice President Shailesh Mishra.
As part of the next phase of this project, Brookfield Renewable’s Irish business plans to leverage the PCI Platform to provide its customers with a dedicated application for on-demand access to energy data and enhanced reporting. PCI’s Platform offers unmatched functionality for renewable energy players to optimize their portfolios, including co-optimization of Energy Storage Systems (ESS) in wholesale power markets. PCI works with numerous renewable energy providers, including BHE Renewables, RWE Renewables, Iberdrola, Acciona, Xcel Energy, DTE Energy, and others.
About Brookfield Renewable
Brookfield Renewable operates one of the world’s largest publicly traded, pure-play renewable power platforms. Its portfolio consists of hydroelectric, wind, solar, distributed generation, and storage facilities in North America, South America, Europe, and Asia, and totals approximately 20,000 megawatts of installed capacity and an approximately 23,000-megawatt development pipeline.
Brookfield Renewable’s Irish onshore wind portfolio is a fully integrated development, operations, and renewable energy solutions business with 365 MW of operating capacity and a significant onshore wind development pipeline. Further information is available at www.brookfield.com/our-businesses/renewable-power .
About Power Costs, Inc. (PCI)
PCI is the leading provider of energy trading software, superior customer support, and value-added services for energy companies worldwide. Founded in 1992, PCI continues to refine and develop new solutions that meet the ever-evolving needs of its clients which include investor-owned, municipal, and cooperative utilities, renewable energy companies, energy marketers and traders, as well as independent power producers. PCI optimizes more than half the power generated in North America and more than 60% of Fortune 500 Utilities in the U.S. are PCI customers. The firm is privately held and based in Norman (OK) with regional offices in Houston (TX), Raleigh (NC), and Mexico City. To learn more, please visit www.powercosts.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210317005052/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom